| Name | Title | Contact Details |
|---|
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases.
Abivax is developing therapies that modulate the body`s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, viral diseases and liver cancer. Abivax is based on innovative research driven by the idea of modulating the body`s natural immune system mechanisms to treat diseases.
VIRxSYS Corporation is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ciitizen is a platform that helps you collect, organize, and share your medical records digitally. Use it to get a second opinion, coordinate with a caregiver, and donate to research.